Related Experiment Video

Updated: Dec 31, 2025

Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

1.1K

Translating Chagasic dilating cardiomyopathy to surgical therapies: An under published global challenge

Zoe C Groom1, Vasileios Zochios2,3, Aristotle D Protopapas4

  • 1Costello Medical Consulting Limited, Cambridge, UK.

SAGE Open Medicine
|January 4, 2020
PubMed

Insights

Chagasic heart failure, a neglected parasitic disease, causes cardiomyopathy and spreads globally. Limited surgical options exist due to economic burdens, highlighting a gap in treatment for this cardiac condition.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Public Health

Background:

  • Chagas disease is a neglected parasitic anthropozoonosis prevalent in the Americas, linked to social deprivation.
  • It is a leading cause of non-ischemic dilating cardiomyopathy in Latin America.
  • The disease is expanding globally through imported and autochthonous transmission, beyond its traditional vector range.

Purpose of the Study:

  • To review the existing evidence on surgical interventions for Chagasic heart failure.
  • To provide a narrative on the translational management of this condition.
  • To highlight the scarcity of literature on advanced therapies like assist devices and transplantation for Chagasic heart failure.

Main Methods:

  • Literature review of surgical management in Chagasic heart failure.
  • Analysis of translational aspects and economic burdens.
  • Examination of treatment accessibility for affected populations.

Main Results:

  • There is very limited literature available on surgical interventions, including mechanical assist devices and heart transplantation, for Chagasic heart failure.
  • The economic burden associated with Chagasic heart failure often presents an insurmountable barrier for young patients.
  • Limited access to advanced medical procedures exacerbates the challenges in managing this condition.

Conclusions:

  • Chagasic heart failure represents a neglected translational model for parasymphatholytic non-ischemic cardiac failure.
  • The lack of surgical options and economic constraints severely impacts patient outcomes.
  • Further research and accessible treatment strategies are crucial for addressing this global health challenge.

Keywords:
American trypanosomiasisChagas diseaseglobal healthtropical diseasetropical surgery

More Related Videos

Gene Transfer for Ischemic Heart Failure in a Preclinical Model07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.3K
Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.3K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
260
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
388
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
311
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
195
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
396
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
321